BioAtla Inc. (BCAB)
0.28
-0.02 (-6.64%)
At close: Apr 04, 2025, 3:59 PM
0.31
10.64%
After-hours: Apr 04, 2025, 04:28 PM EDT
-6.64% (1D)
| Bid | 0.26 |
| Market Cap | 16.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.44 |
| PE Ratio (ttm) | -0.19 |
| Forward PE | -0.37 |
| Analyst | Hold |
| Ask | 0.35 |
| Volume | 882,711 |
| Avg. Volume (20D) | 852,344 |
| Open | 0.29 |
| Previous Close | 0.30 |
| Day's Range | 0.26 - 0.32 |
| 52-Week Range | 0.24 - 3.99 |
| Beta | 1.07 |
About BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, mel...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 61
Stock Exchange NASDAQ
Ticker Symbol BCAB
Website https://www.bioatla.com
Analyst Forecast
According to 3 analyst ratings, the average rating for BCAB stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 970.66% from the latest price.
Stock Forecasts5 days ago
-7.1%
BioAtla shares are trading lower after Citizens Ca...
Unlock content with
Pro Subscription
1 week ago
-4.92%
BioAtla shares are trading lower after the company announced it is restructuring and realigning resources, which includes a workforce reduction of over 30%.
